B

BioInvent International AB
STO:BINV

Watchlist Manager
BioInvent International AB
STO:BINV
Watchlist
Price: 25 SEK -5.66%
Market Cap: 1.6B SEK

P/OCF
Price to OCF

-4.3
Current
-8.3
Median
19.4
Industry
Higher than median
Lower than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
-4.3
=
Market Cap
1.6B SEK
/
Operating Cash Flow
-380.6m SEK
 
SE
B
BioInvent International AB
STO:BINV
Average P/OCF: 16.3
Negative Multiple: -4.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -228 196.1
US
Abbvie Inc
NYSE:ABBV
17.5
US
Amgen Inc
NASDAQ:AMGN
13.5
US
Gilead Sciences Inc
NASDAQ:GILD
12.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -247.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -493
AU
CSL Ltd
ASX:CSL
24.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -79.6
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.5

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A